Ambu A/S (0MJF.IL)
| Previous close | 83.81 |
| Open | 82.92 |
| Bid | 80.90 x 0 |
| Ask | 85.04 x 0 |
| Day's range | 82.54 - 84.46 |
| 52-week range | 61.48 - 194.75 |
| Volume | |
| Avg. volume | 210,692 |
| Market cap | 21.068B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 85.43 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.29 (0.35%) |
| Ex-dividend date | 15 Dec 2021 |
| 1y target est | N/A |
- Globe Newswire
Annual Report 2021/22
Today, Ambu issues the Annual Report for the financial year 2021/22, including Sustainability Report and Remuneration Report. The reports can be found at Ambu.com. Attachments Remuneration Report 2021-22 - Ambu Sustainability Report 2021-2022 - Ambu Ambu-2022-09-30-en Annual Report 2021-22 - Ambu
- Globe Newswire
ANNUAL RESULTS 2021/22 (EARNINGS RELEASE)
Ambu delivered 4% organic revenue growth for the year 2021/22. Global Endoscopy Solutions (previously named Visualisation) revenues grew organically by 1%, mainly driven by strong growth in the ENT (Ear-Nose-Throat) and urology segments, offset by declining sales in the pulmonology segment, mostly due to high Covid-19 comparables. The Anaesthesia and Patient Monitoring businesses posted positive organic growth of 5% and 13%, respectively, driven by pent-up demand and recovery from the Covid-19 p
- Globe Newswire
Ambu A/S: Financial Calendar
This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting for the financial year 2022/23. Please see attached PDF. CONTACTS Thomas Frederik Schmidt Chief Financial Officer tfsc@ambu.com / +45 2084 0500Nicolai Thomsen Director, Investor Relations & Strategic Financial Planning nith@ambu.com / +45 2620 8047 Attachment Financial calendar_Company_Announcement_2021_22_no_14
